Small cell tumors of bone

Advances in Anatomic Pathology

Volumn 17, Issue 1, 2010, Pages 1-11

  Li, Shaoying ^a   Siegal, Gene P ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Bone; Ewing sarcoma; Langerhans cell histiocytosis; Leukemia; Lymphoma; Multiple myeloma; Neuroblastoma; PNET; Rhabdomyosarcoma; Small cell osteosarcoma; Small cell tumor

Indexed keywords

M PROTEIN;

AGE DISTRIBUTION; BONE RADIOGRAPHY; BONE TUMOR; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; EWING SARCOMA; HISTIOCYTOSIS X; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LYMPHOMA; MOLECULAR GENETICS; MULTIPLE MYELOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; OSTEOSARCOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SEX DIFFERENCE; SMALL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LEUKEMIA; LYMPHOMA; MIDDLE AGED; MULTIPLE MYELOMA; NEUROBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; OSTEOSARCOMA; PLASMACYTOMA; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SARCOMA, SMALL CELL;

EID: 75449119181     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181bb6b9c     Document Type: Review

References (107)

1. Cusmariu JR, Lopez-Ben R, Siegal GP, et al. Enlarging toe mass in a 13-year-old girl (extraosseous Ewing's sarcoma). Clin Orthop Relat Res 2001;390:259-269.
2. Ushigome U, Sorensen PH. Ewing sarcoma/Primitive neuroectodermal tumor (PNET). In: Fletcher CDMUK, Mertens F, eds. World Health Organization Classification of Tumors Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon: IARC Press; 2002:298-300.
3. Maygarden S, Askin FB, Siegal GP, et al. Ewing's sarcoma of bone in babies and toddlers: A clinicopathologic report from the Intergroup Ewing's Study. Cancer. 1993;71:2109-2118.
4. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am. 2000;82:667-674.
5. Shirley SA, Gilula LA, Siegal GP, et al. Roentgenographicpathologic correlation of diffuse sclerosis in Ewing's sarcoma of bone. Skeletal Radiol. 1984;12:69-78.
6. Reinus WR, Gilula LA, Shirley SK, et al. Radiographic appearance of Ewing sarcoma of the hands and feet: report from the intergroup Ewing's sarcoma study. Am J Roentgenol. 1985;144:331-336.
7. Nascimento AG, Unii KK, Pritchard DJ, et al. A clinicopathologic study of 20 cases of large-cell (atypical) Ewing's sarcoma of bone. Am J Surg Pathol. 1980;4:29-36.
8. Bridge JA, Fidler ME, Neff JR, et al. Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift. Am J Surg Pathol. 1999;23:159-165.
9. Hauben E, van den Broek LC, Van Marck E, et al. Adamantinoma-like Ewing's sarcoma and Ewing's-like adamantinoma. The t(11; 22), t(21; 22) status. J Pathol. 2001; 195:218-221.
10. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: A study of 66 genetically confirmed cases. Am J Surg Pathol. 2005; 29:1025-1033.
11. Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 1991;67:1886-1893.
12. Granter SR, Renshaw AA, Fletcher CD, et al. CD99 reactivity in mesenchymal chondrosarcoma. Hum Pathol. 1996;27:1273-1276.
13. LaeMW, Roche PC, Jin L, et al. Desmoplastic small round cell tumor: A clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol. 2002;26:823-835.
14. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, et al. Differentiating lymphoblastic lymphoma and Ewing's sarcoma: lymphocyte markers and gene rearrangement. Mod Pathol. 2001;14:1175-1182.
15. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein expression: A study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol. 2000;24:1657-1662.
16. Llombart-Bosch A, Navarro S. Immunohistochemical detection of EWS and FLI-1 proteins in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol. 2001;9:255-260.
17. Franchi A, Pasquinelli G, Cenacchi G, et al. Immunohistochemical and ultrastructural investigation of neural differentiation in Ewing sarcoma/PNET of bone and soft tissues. Ultrastruct Pathol. 2001;25:219-225.
18. Gu M, Antonescu CR, Guiter G, et al. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol. 2000;24:410-416.
19. Siegal GP, Miller EW, Mirmiran SA, et al. Collagen and laminin immunoreactivity in Ewing's sarcoma. Support for an uncommitted mesenchymal cell derivation. Pediatr Pathol. 1986;5:485-487.
20. Aurias A, Rimbaut C, Buffe D, et al. Translocation of chromosome 22 in Ewing's sarcoma. C R Seances Acad Sci III. 1983;296:1105-1107.
21. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6:146-151.
22. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995;10:1229-1234.
23. Kaneko Y, Yoshida K, Handa M, et al. Fusion of an ETSfamily gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer. 1996;15:115-121.
24. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997;14:1159-1164.
25. Urano F, Umezawa A, Hong W, et al. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun. 1996;219:608-612.
26. Khoury JD. Ewing sarcoma family of tumors: A model for the new era of integrated laboratory diagnostics. Expert Rev Mol Diagn. 2008;8:97-105.
27. Burchill SA. Molecular abnormalities in Ewing's sarcoma. Expert Rev Anticancer Ther 2008;8:1675-1687.
28. Leavey PJ, Collier AB. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther. 2008;8:617-624.
29. Shirley SK, Askin FB, Gilula LA, et al. Ewing's sarcoma in bones of the hands and feet: A clinicopathologic study and review of the literature. J Clin Oncol. 1985;3:686-697.
30. Siegal GP, Oliver W, Reinus WR, et al. Primary Ewing's sarcoma involving the bones of the head and neck. Cancer. 1987;60:2829-2840.
31. Sim FH, Unni KH, Beabout JW, et al. Osteosarcoma with small cells simulating Ewing's tumor. J Bone Joint Surg Am. 1979;61:207-215.
32. Ayala A, Ro J, Raymond A, et al. Small cell osteosarcoma. A clinicopathologic study of 27 cases. Cancer. 1989;64: 2162-2173.
33. Bertoni F, Present D, Bacchini P, et al. The Istituto Rizzoli experience with small cell osteosarcoma. Cancer. 1989;64: 2591-2599.
34. Nakajima H, Sim FH, Bond JR, et al. Small cell osteosarcoma of bone. Review of 72 cases. Cancer. 1997;79:2095-2106.
35. Klein MJ, Siegal GP. Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol. 2006;125:555-581.
36. Robinson LH, Pitt MJ, Jaffe KA, et al. Small cell osteosarcoma of the soft tissue/periosteum. Skeletal Radiol. 1995;24:462-465.
37. Devaney K, Vinh TN, Sweet DE. Small cell osteosarcoma of bone: An immunohistochemical study with differential diagnostic considerations. Hum Pathol. 1993;24:1211-1225.
38. Devoe K, Weidner N. Immunohistochemistry of small roundcell tumors. Semin Diagn Pathol. 2000;17:216-224.
39. Ragland BD, Bell WC, Lopez-Ben RR, et al. Cytogenetics and molecular biology of osteosarcoma. Lab Invest. 2002; 82:365-373.
40. Bell WC, Siegal GP. Molecular Pathology of Osteosarcoma. In: Heymann D, ed. Bone Cancer: Progression and Therapeutic Approaches. Philadelphia: Elsevier; 2009:193-200.
41. Mckenna RW, Kuehl WM, et al. Plasma cell neoplasms. In: Swerdlow S, Harris N, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008:202-209.
42. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
43. Ries LAG, Krapcho M, Stinchcomb DG, et al. SEER Cancer Statistics Review. 1975-2005. Bethesda: National Cancer Institute; 2008.
44. Roodman GD. Novel targets for myeloma bone disease. Expert Opin Ther Targets. 2008;12:1377-1387.
45. Yata K, Abe M, Matsumoto T. Mechanisms for formation of myeloma bone disease. Clin Calcium. 2008;18:438-446.
46. Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-488.
47. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117:882-885.
48. Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121-131.
49. Grogan TM, Durie BG, Spier CM, et al. Myelomonocytic antigen positive multiple myeloma. Blood. 1989;73:763-769.
50. Sawyer JR, Waldron JA, Jagannath S, et al. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:41-49.
51. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res. 2004;64:1546-1558.
52. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489-3495.
53. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23:3412-3420.
54. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am. 1999;13:1295-1314.
55. Nagura E. Prognostic factors in multiple myeloma. Nippon Rinsho. 2007;65:2351-2356.
56. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21: 529-534.
57. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
58. Baar J, Burkes RL, Gospodarowicz M. Primary non- Hodgkin's lymphoma of bone. Semin Oncol. 1999;26: 270-275.
59. Gianelli U, Patriarca C, Moro A, et al. Lymphomas of the bone: A pathological and clinical study of 54 cases. Int J Surg Pathol. 2002;10:257-266.
60. Unni KKHP. Malignant lymphoma. In: Fletcher CDMUK, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:306-308.
61. Heyning FH, Hogendoorn PC, Kramer MH, et al. Primary non-Hodgkin's lymphoma of bone: A clinicopathological investigation of 60 cases. Leukemia. 1999;13:2094-2098.
62. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, et al. Precursor B-lymphoblastic lymphoma presenting as a solitary bone tumor and mimicking Ewing's sarcoma: A report of four cases and review of the literature. Am J Surg Pathol. 1998; 22:795-804.
63. Takemoto S, Matsuoka M, Sakata K, et al. Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Leukemia. 1996;10:333-337.
64. Ostrowski ML, Inwards CY, Strickler JG, et al. Osseous Hodgkin disease. Cancer. 1999;85:1166-1178.
65. Ostrowski ML, Unni KK, Banks PM, et al. Malignant lymphoma of bone. Cancer. 1986;58:2646-2655.
66. Marsh WL Jr, Bylund DJ, Heath VC, et al. Osteoarticular and pulmonary manifestations of acute leukemia. Case report and review of the literature. Cancer. 1986;57:385-390.
67. Meis JM, Butler JJ, Osborne BM, et al. Granulocytic sarcoma in nonleukemic patients. Cancer. 1986;58:2697-2709.
68. Welch P, Grossi C, Carroll A, et al. Granulocytic sarcoma with an indolent course and destructive skeletal disease. Tumor characterization with immunologic markers, electron microscopy, cytochemistry, and cytogenetic studies. Cancer. 1986;57:1005-1010.
69. Maitra AKV. Disease of Infancy and Childhood. In: Kumar VAA, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders; 2005: 469-508.
70. Delellis RMS. The Adrenal Glands. In: Stacey E, Mills DC, Joel KG, et al, eds. Sternberg's Diagnostic Surgical Pathology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004:648.
71. Sohara Y, Shimada H, DeClerck YA. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Lett. 2005;228:203-209.
72. Howman-Giles R, Shaw PJ, Uren RF, et al. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007; 37:286-302.
73. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86:349-363.
74. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224:1121-1124.
75. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: A report from the children's cancer group. Cancer. 2001;92:2699-2708. (Pubitemid 33049455)
76. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954-1961.
77. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334: 225-230. (Pubitemid 26030673)
78. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27:1026-1033.
79. Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10:4-12.
80. Evans AE, Gerson J, Schnaufer L. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr. 1976;44:49-54.
81. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11: 1466-1477.
82. De Young BR. Langerhans cell histiocytosis. In: Fletcher CDMUK, Mertens F, eds. Pathology and Genetics of Tumurs of Soft Tissue and Bone. Lyon: IARC Press; 2002:345-346.
83. Siegal GP, Dehner LP, Rosai J. Histiocytosis X (Langerhans' cell granulomatosis) of the thymus. A clinicopathologic study of four childhood cases. Am J Surg Pathol. 1985;9:117-124.
84. Lieberman PH, Jones CR, Steinman RM, et al. Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol. 1996;20:519-552.
85. Pileri SA, Grogan TM, Harris N, et al. Tumors of histiocytes and accessory dendritic cells: An immunohistochemical approach to classification from the international lymphoma study group based on 61 cases. Histopathology. 2002;41:1-29.
86. Emile JF, Wechsler J, Brousse N, et al. Langerhans' cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol. 1995;19:636-641.
87. Bechan GI, Egeler RM, Arceci RJ. Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol. 2006; 254:1-43.
88. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med. 1994;331:154-160.
89. Murakami I, Gogusev J, Fournet JC, et al. Detection of molecular cytogenetic aberrations in langerhans cell histiocytosis of bone. Hum Pathol. 2002;33:555-560. (Pubitemid 34747877)
90. Schouten B, Egeler RM, Leenen PJ, et al. Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2002;24:727-732.
91. Betts DR, Leibundgut KE, Feldges A, et al. Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer. 1998;77:552-555.
92. Nezelof C, Frileux-Herbet F, Cronier-Sachot J. Disseminated histiocytosis X: Analysis of prognostic factors based on a retrospective study of 50 cases. Cancer. 1979;44:1824-1838.
93. Howarth DM, Gilchrist GS, Mullan BP, et al. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999;85:2278-2290.
94. Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995;76: 2471-2484.
95. Pollono D, Rey G, Latella A, et al. Reactivation and risk of sequelae in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48:696-699.
96. Joshi D, Anderson JR, Paidas C, et al. Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group. Pediatr Blood Cancer. 2004;42:64-73.
97. Lucas DR, Ryan JR, Zalupski MM, et al. Primary embryonal rhabdomyosarcoma of long bone. Case report and review of the literature. Am J Surg Pathol. 1996;20:239-244.
98. Kariya S, Cureoglu S, Schachern PA, et al. Histopathological temporal bone study of the metastatic rhabdomyosarcoma. Auris Nasus Larynx. 2009;36:221-223.
99. Sbeity S, Abella A, Arcand P, et al. Temporal bone rhabdomyosarcoma in children. Int J Pediatr Otorhinolaryngol. 2007;71:807-814.
100. Durve DV, Kanegaonkar RG, Albert D, et al. Pediatric rhabdomyosarcoma of the ear and temporal bone. Clin Otolaryngol Allied Sci. 2004;29:32-37.
101. Wang NP, Marx J, McNutt MA, et al. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol. 1995;147:1799-1810.
102. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol. 2001;25:1150-1157.
103. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the pediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3:113-117. (Pubitemid 23079791)
104. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869-2872.
105. Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: An update. Arch Pathol LabMed. 2006;130:1454-1465.
106. Koufos A, Hansen MF, Copeland NG, et al. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature. 1985;316:330-334.
107. Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384-2389.